These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16720620)

  • 1. Biologically active molecules that reduce polyglutamine aggregation and toxicity.
    Desai UA; Pallos J; Ma AA; Stockwell BR; Thompson LM; Marsh JL; Diamond MI
    Hum Mol Genet; 2006 Jul; 15(13):2114-24. PubMed ID: 16720620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor.
    Pollitt SK; Pallos J; Shao J; Desai UA; Ma AA; Thompson LM; Marsh JL; Diamond MI
    Neuron; 2003 Nov; 40(4):685-94. PubMed ID: 14622574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
    Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
    Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation.
    Wang J; Gines S; MacDonald ME; Gusella JF
    BMC Neurosci; 2005 Jan; 6():1. PubMed ID: 15649316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F-actin binding regions on the androgen receptor and huntingtin increase aggregation and alter aggregate characteristics.
    Angeli S; Shao J; Diamond MI
    PLoS One; 2010 Feb; 5(2):e9053. PubMed ID: 20140226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation.
    Shao J; Welch WJ; Diamond MI
    FEBS Lett; 2008 May; 582(12):1637-42. PubMed ID: 18423405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.
    Ehrnhoefer DE; Duennwald M; Markovic P; Wacker JL; Engemann S; Roark M; Legleiter J; Marsh JL; Thompson LM; Lindquist S; Muchowski PJ; Wanker EE
    Hum Mol Genet; 2006 Sep; 15(18):2743-51. PubMed ID: 16893904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila.
    Chan HY; Warrick JM; Gray-Board GL; Paulson HL; Bonini NM
    Hum Mol Genet; 2000 Nov; 9(19):2811-20. PubMed ID: 11092757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin.
    Caron NS; Desmond CR; Xia J; Truant R
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14610-5. PubMed ID: 23898200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase.
    Scappini E; Koh TW; Martin NP; O'Bryan JP
    Hum Mol Genet; 2007 Aug; 16(15):1862-71. PubMed ID: 17550941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
    Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
    Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.
    Lee WC; Yoshihara M; Littleton JT
    Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3224-9. PubMed ID: 14978262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease.
    Ravikumar B; Vacher C; Berger Z; Davies JE; Luo S; Oroz LG; Scaravilli F; Easton DF; Duden R; O'Kane CJ; Rubinsztein DC
    Nat Genet; 2004 Jun; 36(6):585-95. PubMed ID: 15146184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules.
    Tanaka M; Machida Y; Nukina N
    J Mol Med (Berl); 2005 May; 83(5):343-52. PubMed ID: 15759103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor.
    Diamond MI; Robinson MR; Yamamoto KR
    Proc Natl Acad Sci U S A; 2000 Jan; 97(2):657-61. PubMed ID: 10639135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid modulation of androgen receptor nuclear aggregation and cellular toxicity is associated with distinct forms of soluble expanded polyglutamine protein.
    Welch WJ; Diamond MI
    Hum Mol Genet; 2001 Dec; 10(26):3063-74. PubMed ID: 11751688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inefficient degradation of truncated polyglutamine proteins by the proteasome.
    Holmberg CI; Staniszewski KE; Mensah KN; Matouschek A; Morimoto RI
    EMBO J; 2004 Oct; 23(21):4307-18. PubMed ID: 15470501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model.
    Wang W; Duan W; Igarashi S; Morita H; Nakamura M; Ross CA
    Neurobiol Dis; 2005 Nov; 20(2):500-8. PubMed ID: 15908226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleation of huntingtin aggregation in cells.
    Wetzel R
    Nat Chem Biol; 2006 Jun; 2(6):297-8. PubMed ID: 16710335
    [No Abstract]   [Full Text] [Related]  

  • 20. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases.
    Krainc D
    Arch Neurol; 2010 Apr; 67(4):388-92. PubMed ID: 20385902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.